FDA accepts NDA for Vesneo

The FDA has accepted Bausch + Lomb and Nicox’s new drug application for Vesneo for review, according to a press release from Valeant Pharmaceuticals. “The acceptance for review of the Vesneo NDA by the FDA marks an important milestone in our effort to bring a new treatment to patients with open angle glaucoma and ocular hypertension,” J. Michael Pearson, CEO and chairman of Valeant, said in the release.